Search

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US

Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom

Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US

BI announces new data for GILOTRIF®, affirming its activity in SCC of the lung with findings presented at the IASLC 2020. View ISI, PI and Med Guide.

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

U.S. FDA grants Breakthrough Therapy designation for MASH

Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis

Search

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom

Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Interchangeable Biosimilar Now on Express Scripts® Formulary

U.S. FDA grants Breakthrough Therapy designation for MASH

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom

Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Interchangeable Biosimilar Now on Express Scripts® Formulary

U.S. FDA grants Breakthrough Therapy designation for MASH